<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01090661</url>
  </required_header>
  <id_info>
    <org_study_id>MIPO2800209</org_study_id>
    <nct_id>NCT01090661</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects</brief_title>
  <official_title>A Randomized Double-Blinded Crossover Trial to Define the ECG Effects of Mipomersen (ISIS 301012) Using a Therapeutic and Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kastle Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kastle Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the electrocardiogram (ECG) effects of mipomersen administered as a 200-mg
      subcutaneous (SC) therapeutic and a 200-mg intravenous (IV; [2-hour infusion])
      supra-therapeutic dose relative to placebo in healthy adult male and female subjects; and to
      evaluate the safety and pharmacokinetics (PK) of mipomersen when administered as a single
      therapeutic (200 mg) SC and a single, supra-therapeutic (200 mg) IV dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double-blind, single-site, crossover study in healthy male and
      female subjects to determine if mipomersen administered as a single therapeutic (200 mg) SC
      and a single supra-therapeutic (200 mg) IV dose delays cardiac repolarization as determined
      by the measurement of QT/corrected QT (QTc) interval. A total of 60 healthy male and female
      subjects will be enrolled in this 4-way crossover study, randomly assigned to 1 of 8
      treatment sequences, and cross over into 4 treatment periods where each subject will receive
      both a single SC injection and a single IV infusion during each period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in QTcF (corrected Frederica's CT interval)</measure>
    <time_frame>ECG monitoring up to 24 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ECG intervals (QTcB (corrected Bazett's QT interval), HR (heart rate, PR, QRS, and QT)</measure>
    <time_frame>ECG monitoring up to 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in ECG morphological patterns</measure>
    <time_frame>ECG monitoring up to 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between delta delta QTc interval and plasma mipomersen concentrations</measure>
    <time_frame>ECG monitoring up to 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent Adverse Events</measure>
    <time_frame>Assessed at each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mipomersen plasma pharmacokinetic (PK) parameters: Area Under the Curve (AUC 0-22.5h), Maximum Concentration (Cmax), Time to Maximum Concentration (Tmax)</measure>
    <time_frame>Serial PK sampling up to 24 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>mipomersen IV (supra-therapeutic dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg of mipomersen IV / placebo SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mipomersen SC (therapeutic dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg of mipomersen SC / placebo IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>moxifloxacin IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 mg of moxifloxacin IV / placebo SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo IV / placebo SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mipomersen sodium</intervention_name>
    <description>200 mg of mipomersen intravenous (IV) (single dose)</description>
    <arm_group_label>mipomersen IV (supra-therapeutic dose)</arm_group_label>
    <other_name>ISIS 301012</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mipomersen sodium</intervention_name>
    <description>200 mg of mipomersen subcutaneous (SC) (single dose)</description>
    <arm_group_label>mipomersen SC (therapeutic dose)</arm_group_label>
    <other_name>ISIS 301012</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin hydrochloride (AveloxÂ®)</intervention_name>
    <description>400 mg of moxifloxacin intravenous (IV) single dose</description>
    <arm_group_label>moxifloxacin IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo intravenous (IV) single dose</description>
    <arm_group_label>mipomersen SC (therapeutic dose)</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo subcutaneous (SC) single dose</description>
    <arm_group_label>mipomersen IV (supra-therapeutic dose)</arm_group_label>
    <arm_group_label>moxifloxacin IV</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent provided before any study-related procedures are performed.

          -  Body mass index (BMI) of 19 to 32 kg/m2 inclusive.

          -  Subjects can not have consumed nicotine or nicotine-containing products for at least 6
             months before Screening.

          -  Subjects are nonpregnant and nonlactating, surgically sterile, postmenopausal,
             abstinent, or subject or partner is willing to use a reliable method of contraception
             during the study and 5 months after the last dose of investigational product.

        Exclusion Criteria:

          -  History of risk factors for Torsades de Pointes, known Long QT Syndrome, heart
             failure, myocardial infarction, angina, or clinically significant abnormal laboratory
             assessments or family history of Long QT or Brugada Syndrome.

          -  Abnormal screening ECG that is interpreted by the Investigator to be clinically
             significant.

          -  Use of concomitant medications (prescribed or over-the-counter), without the approval
             of the Investigator and Sponsor, within 7 days before the first dose of
             investigational product.

          -  Clinically significant abnormal findings on the physical examination, ECG, blood
             pressure, heart rate, medical history, or clinical laboratory results at Screening or
             before dosing.

          -  History of clinically significant allergies or hematological, endocrine, pulmonary,
             gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease.

          -  Positive test for HIV antibody, hepatitis C antibody, or hepatitis B surface antigen.

          -  Positive test for drugs of abuse, alcohol, or cotinine at Screening or before dosing
             or history of drug or alcohol abuse or dependence within 1 year before Screening.

          -  History of cancer, with the exception of basal cell carcinoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Development, LP</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2010</study_first_submitted>
  <study_first_submitted_qc>March 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2010</study_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antisense</keyword>
  <keyword>ApoB (Apolipoprotein B)</keyword>
  <keyword>LDL (low density lipoprotein)</keyword>
  <keyword>thorough QT</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Mipomersen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

